Enzo Biochem Inc. (ENZ) Company Sales Volume

Sales performance for Enzo Biochem, Inc. (ENZ), based on licensing and diagnostics, is recorded at 0.03. Business scalability is driven by the mass production of automated test kits and reagents. The current development strategy focuses on the systematic improvement of molecular systems and the updating of formulas within the R&D pipeline, which supports the stability of operational activities.

ENZ (Enzo Biochem Inc.) Company Revenue history from 07/04/2022 to 04/26/2025

Comprehensive metric breakdowns and analytics for Enzo Biochem Inc. (ENZ)

- market price and analyst price targets:

Market Price Enzo|ENZ - Price Target Chart

- market capitalization details:

Market Capitalization Enzo Biochem, Inc.|ENZ - Real Price to Acquire Entire Company

- issuer book value statistics:

Share Book Value Enzo Biochem|ENZ - Company Book Value|Market-to-Book Ratio enzo.com|ENZ - Cumulative Company Assets

- debt obligations and liquidity statistics:

- net income and valuation multiples indicators:

ENZ - Net Profit|Expected Net Income Enzo Biochem, Inc.|ENZ - P/E Multiple|Projected Price to Earnings Ratio Enzo|ENZ - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Enzo Biochem, Inc.|ENZ - Operating profit before deduction of amortization|Earnings per share for the trailing year Enzo Biochem|ENZ - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months enzo.com|ENZ - Earnings per share growth in current year|Projected earnings per share growth rate for next year Enzo Biochem, Inc.

- sales volume and revenue indicators:

ENZ - Revenue and Sales Volume|Company Future Sales Volume Enzo|ENZ - Market Cap to Revenue|Market Cap to Expected Sales Ratio Enzo Biochem, Inc.

Summary company analysis:Enzo Biochem, Inc.

This indicator reflects revenue dynamics on a daily basis for the primary screening of the asset, allowing the investor to assess cash flow generation rates and capital volatility risks. Tracking sales for Enzo Biochem, Inc. (ENZ) demonstrates the effectiveness of the company's intellectual property monetization, where income stability depends directly on the demand for its patented DNA labeling technologies amidst fierce competition in the molecular diagnostics market.

Analysis of competing companies